CVPath Research Team Publishes Three Recent Studies in Scientific Journals
APOL1 Genetic Variants Are Associated With Increased Risk of Coronary Atherosclerotic Plaque Rupture in the Black Population
The APOL1 gene encoding the apolipoprotein L1 comprising of two renal risk variants alleles G1 and G2 is linked to increased lifetime risk for end-stage kidney disease in African American patients.
Our latest published article indicating the potential that the APOL1 risk allele carriers may be associated with plaque vulnerability eventually affecting lipid metabolism with an increased risk of plaque rupture can be found here: https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.315788?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Endothelial Recovery in Bare Metal Stents and Drug-Eluting Stents on a Single-Cell Level
“Although the mechanism of the earlier development of neoatherosclerosis in DES implanted segment versus BMS is unclear, it is likely due to the endothelial dysfunction caused by anti-proliferative agents in DES.
The interesting landscapes of different gene expression profiles in the vascular endothelial cells between DES and BMS-treated rabbit iliac arteries have been shown by contemporary available single-cell RNA sequencing technique.”
Efficacy and safety of cerebral embolic protection systems during transcatheter aortic valve replacement: a review of current clinical findings
Cerebrovascular events are one of the most serious consequences after transcatheter aortic valve replacement and more than half of them occur due to procedure-related emboli. Embolic protection devices have the potential to decrease cerebrovascular events during TAVR procedure.
You can find our recent review paper summarizing clinical and pathological data discussing embolic protection devices from our pathological point of view.
Read more here: https://pubmed.ncbi.nlm.nih.gov/34263701/